Imaging Biomarker Market: By Technology, By Applications & By Region - Forecast 2016-2021

  • ID: 3974040
  • Report
  • 165 pages
  • IndustryARC
1 of 3
An imaging biomarker is used as a diagnostic mechanism which can be detected through an imaging technology. A biomarker is a biological molecule found in tissue, blood or other body fluids, which mark the presence of a normal or an abnormal process, or of a condition or disease. Thus, these biomarkers are used to monitor responses of the body to a disease. It can also be used for early detection of diseases such as cancer and therefore increasing the chances of survival of the patient.
Globally, increasing number of hospitals and increased need for toxicity profiling are the prime growth drivers of imaging biomarkers. Growing number of cancer patients and need for early detection is estimated to be an opportunity for the market in the long term. However, high costs of these tests may be a hindrance for wide adoption.
This report identifies the global Imaging Biomarker market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Imaging Biomarker market.

Geographically North America dominates the global imaging biomarker market, and is projected to have fastest growth, owing to higher number of mobile, laptop, and tablet users. Emerging economies in the Asia Pacific region are expected to grow at the highest CAGR owing to rising awareness regarding the imaging biomarkers and continuous improvement in the healthcare infrastructure.

This report segments global imaging biomarker market on the basis of technology, by application, and regional market as follows:
Global Imaging Biomarker Market, by Technology: Positron Emission Tomography, Ultrasound, Magnetic Resonance Imaging, Computed Tomography and Single-Photon Emission Computed Tomography
Global Imaging Biomarker Market, by Application: Personalized Medicines, Drug Discovery and Development, Molecular Diagnostics, Drug Formulation, Disease Diagnosis &Forensic Applications
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

This report identifies all the major companies operating in the global Imaging Biomarker market. Some of the major companies’ profiles in detail are as follows:
Abbott Laboratories
Agilent Technologies Inc.

Siemens Healthcare
Bio-Rad Laboratories Inc.

Becton, Dickinson and Company
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Global Imaging Biomarker – Market Overview

2. Executive Summary

3. Global Imaging Biomarker Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Global Imaging Biomarker – Market Forces
4.1. Drivers
4.1.1. Increased Need for Toxicity Profiling
4.2. Restraints
4.2.1. High Cost of Tests
4.3. Opportunities
4.3.1. High Prevalence of Cancer
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Global Imaging Biomarker Market - By Technology
5.1. Positron Emission Tomography
5.2. Ultrasound
5.3. Magnetic Resonance Imaging
5.4. Computed Tomography
5.5. Single-Photon Emission Computed Tomography

6. Global Imaging Biomarker Market - By Application
6.1. Personalized Medicines
6.2. Drug Discovery and Development
6.3. Molecular Diagnostics
6.4. Drug Formulation
6.5. Disease Diagnosis
6.6. Forensic Applications

7. Global Imaging Biomarker Market - By Geography (2014-2021)
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW

8. Global Imaging Biomarker – Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract

9. Company Profiles (Top 10 Companies)
9.1. Abbott Laboratories
9.1.1. Introduction
9.1.2. Financials
9.1.3. Key Insights
9.1.4. Key Strategy
9.1.5. Product Portfolio
9.1.6. SWOT Analysis
9.2. Agilent Technologies Inc.
9.2.1. Introduction
9.2.2. Financials
9.2.3. Key Insights
9.2.4. Key Strategy
9.2.5. Product Portfolio
9.2.6. SWOT Analysis
9.3. Biocrates Life Sciences AG
9.3.1. Introduction
9.3.2. Financials
9.3.3. Key Insights
9.3.4. Key Strategy
9.3.5. Product Portfolio
9.3.6. SWOT Analysis
9.4. Bio-Rad Laboratories Inc.
9.4.1. Introduction
9.4.2. Financials
9.4.3. Key Insights
9.4.4. Key Strategy
9.4.5. Product Portfolio
9.4.6. SWOT Analysis
9.5. Becton, Dickinson and Company
9.5.1. Introduction
9.5.2. Financials
9.5.3. Key Insights
9.5.4. Key Strategy
9.5.5. Product Portfolio
9.5.6. SWOT Analysis
9.6. Affymetrix Inc.
9.6.1. Introduction
9.6.2. Financials
9.6.3. Key Insights
9.6.4. Key Strategy
9.6.5. Product Portfolio
9.6.6. SWOT Analysis
9.7. F. Hoffmann La Roche Ltd.
9.7.1. Introduction
9.7.2. Financials
9.7.3. Key Insights
9.7.4. Key Strategy
9.7.5. Product Portfolio
9.7.6. SWOT Analysis
9.8. Siemens Healthcare
9.8.1. Introduction
9.8.2. Financials
9.8.3. Key Insights
9.8.4. Key Strategy
9.8.5. Product Portfolio
9.8.6. SWOT Analysis
9.9. Danaher Corporation
9.9.1. Introduction
9.9.2. Financials
9.9.3. Key Insights
9.9.4. Key Strategy
9.9.5. Product Portfolio
9.9.6. SWOT Analysis
9.10. Qiagen NV
9.10.1. Introduction
9.10.2. Financials
9.10.3. Key Insights
9.10.4. Key Strategy
9.10.5. Product Portfolio
9.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown